Previous close | 252.86 |
Open | 251.30 |
Bid | 238.77 x 900 |
Ask | 251.78 x 800 |
Day's range | 245.23 - 253.05 |
52-week range | 132.24 - 255.18 |
Volume | |
Avg. volume | 1,096,020 |
Market cap | 37.162B |
Beta (5Y monthly) | 0.69 |
PE ratio (TTM) | 36.50 |
EPS (TTM) | 6.93 |
Earnings date | 24 Oct 2024 - 28 Oct 2024 |
Forward dividend & yield | 2.12 (0.84%) |
Ex-dividend date | 15 Aug 2024 |
1y target est | 226.90 |
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 96,812 shares of ResMed Inc. ResMed Inc is a global leader in the development, manufacturing, and marketing of medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases.
Learn more about ResMed’s 2030 strategy to accelerate growthJoin in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast link